A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
about
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.An overview of the role of carfilzomib in the treatment of multiple myeloma.
P2860
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A clinical update on the role ...... or refractory multiple myeloma
@ast
A clinical update on the role ...... or refractory multiple myeloma
@en
A clinical update on the role ...... or refractory multiple myeloma
@nl
type
label
A clinical update on the role ...... or refractory multiple myeloma
@ast
A clinical update on the role ...... or refractory multiple myeloma
@en
A clinical update on the role ...... or refractory multiple myeloma
@nl
prefLabel
A clinical update on the role ...... or refractory multiple myeloma
@ast
A clinical update on the role ...... or refractory multiple myeloma
@en
A clinical update on the role ...... or refractory multiple myeloma
@nl
P2093
P2860
P356
P1476
A clinical update on the role ...... or refractory multiple myeloma
@en
P2093
B. Franken
H. M. Lokhorst
J. C. Cloos
N. W. C. J. van de Donk
S. Zweegman
P2860
P304
P356
10.1177/2040620716667275
P407
P577
2016-12-01T00:00:00Z